JP2021183587A - 複素環化合物 - Google Patents

複素環化合物 Download PDF

Info

Publication number
JP2021183587A
JP2021183587A JP2020090111A JP2020090111A JP2021183587A JP 2021183587 A JP2021183587 A JP 2021183587A JP 2020090111 A JP2020090111 A JP 2020090111A JP 2020090111 A JP2020090111 A JP 2020090111A JP 2021183587 A JP2021183587 A JP 2021183587A
Authority
JP
Japan
Prior art keywords
group
compound
mixture
groups
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020090111A
Other languages
English (en)
Japanese (ja)
Inventor
智章 蓮井
Tomoaki Hasui
達 味上
Satoshi Mikami
徹 山下
Toru Yamashita
信二 中村
Shinji Nakamura
真二 森本
Shinji Morimoto
稔博 今枝
Toshihiro Imaeda
和明 ▲高▼見
Kazuaki Takami
將揮 大仁
Masaki Daini
広行 筧
Hiroyuki Kakei
実 中村
Minoru Nakamura
扶美恵 山口
Fumie Yamaguchi
春翔 王
Chun Xiang Wang
幸恵 ▲高▼嶋
yukie Takashima
信 鎌田
Makoto Kamata
裕哉 大黒
Yuya Oguro
周平 池田
Shuhei Ikeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to JP2020090111A priority Critical patent/JP2021183587A/ja
Priority to ARP210101387A priority patent/AR122143A1/es
Priority to TW110118337A priority patent/TW202208346A/zh
Priority to IL298275A priority patent/IL298275A/en
Priority to PCT/IB2021/000337 priority patent/WO2021234451A1/en
Priority to BR112022023503A priority patent/BR112022023503A2/pt
Priority to KR1020227044430A priority patent/KR20230015946A/ko
Priority to AU2021276623A priority patent/AU2021276623A1/en
Priority to US17/999,514 priority patent/US12590086B2/en
Priority to JP2022570532A priority patent/JP7734153B2/ja
Priority to CN202180059093.3A priority patent/CN116171276A/zh
Priority to CA3178798A priority patent/CA3178798A1/en
Priority to MX2022014576A priority patent/MX2022014576A/es
Priority to EP21737769.6A priority patent/EP4153581A1/en
Publication of JP2021183587A publication Critical patent/JP2021183587A/ja
Priority to JP2025139595A priority patent/JP2025170366A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020090111A 2020-05-22 2020-05-22 複素環化合物 Pending JP2021183587A (ja)

Priority Applications (15)

Application Number Priority Date Filing Date Title
JP2020090111A JP2021183587A (ja) 2020-05-22 2020-05-22 複素環化合物
AU2021276623A AU2021276623A1 (en) 2020-05-22 2021-05-20 3-((1H-pyrazol-4-yl)methyl)-6'-(phenyl)-2H-(1,2'-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression
US17/999,514 US12590086B2 (en) 2020-05-22 2021-05-20 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression
IL298275A IL298275A (en) 2020-05-22 2021-05-20 3-((1h-pyrazol-4-yl)methyl)-6'-(phenyl)-2h-(2,1'-bipyridine)-2-one derivatives and related compounds as gpr139 antagonists for use in a method of treating, for example, depression
PCT/IB2021/000337 WO2021234451A1 (en) 2020-05-22 2021-05-20 3-((1h-pyrazol-4-yl)methyl)-6'-(phenyl)-2h-(1,2'-bipyridin)-2-one derivatives and related compounds as gpr139 antagonists for use in a method of treatment of e.g. depression
BR112022023503A BR112022023503A2 (pt) 2020-05-22 2021-05-20 Derivados de 3-((1h-pirazol-4-il)metil)-6'-(fenil)-2h-(1,2'-bipiridin)-2-ona e compostos relacionados como antagonistas de gpr139 para uso em método de tratamento de, por exemplo, depressão
KR1020227044430A KR20230015946A (ko) 2020-05-22 2021-05-20 예를 들어 우울증의 치료 방법에 사용하기 위한 gpr139 길항제로서의 3-((1h-피라졸-4-일)메틸)-6'-(페닐)-2h-(1,2'-비피리딘)-2-온 유도체 및 관련 화합물
ARP210101387A AR122143A1 (es) 2020-05-22 2021-05-20 Compuestos heterocíclicos
TW110118337A TW202208346A (zh) 2020-05-22 2021-05-20 雜環化合物
JP2022570532A JP7734153B2 (ja) 2020-05-22 2021-05-20 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物
CN202180059093.3A CN116171276A (zh) 2020-05-22 2021-05-20 用于治疗e.g.抑郁症的方法中的作为grp139拮抗剂的3-((1h-吡唑-4-基)甲基)-6'-(苯基)-2h-[1,2'-联吡啶]-2-酮衍生物和相关化合物
CA3178798A CA3178798A1 (en) 2020-05-22 2021-05-20 3-((1h-pyrazol-4-yl)methyl)-6'-(phenyl)-2h-(1,2'-bipyridin)-2-one derivatives and related compounds as gpr139 antagonists for use in a method of treatment of e.g. depression
MX2022014576A MX2022014576A (es) 2020-05-22 2021-05-20 Derivados de 3-((1h-pirazol-4-il)metil)-6'-(fenil)-2h-(1,2'-bipiri din)-2-ona y compuestos relacionados como antagonistas de gpr139 para usarse en un método de tratamiento, por ejemplo, contra la depresión.
EP21737769.6A EP4153581A1 (en) 2020-05-22 2021-05-20 3-((1h-pyrazol-4-yl)methyl)-6'-(phenyl)-2h-(1,2'-bipyridin)-2-one derivatives and related compounds as gpr139 antagonists for use in a method of treatment of e.g. depression
JP2025139595A JP2025170366A (ja) 2020-05-22 2025-08-25 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020090111A JP2021183587A (ja) 2020-05-22 2020-05-22 複素環化合物

Publications (1)

Publication Number Publication Date
JP2021183587A true JP2021183587A (ja) 2021-12-02

Family

ID=76797026

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020090111A Pending JP2021183587A (ja) 2020-05-22 2020-05-22 複素環化合物
JP2022570532A Active JP7734153B2 (ja) 2020-05-22 2021-05-20 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物
JP2025139595A Pending JP2025170366A (ja) 2020-05-22 2025-08-25 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022570532A Active JP7734153B2 (ja) 2020-05-22 2021-05-20 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物
JP2025139595A Pending JP2025170366A (ja) 2020-05-22 2025-08-25 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物

Country Status (13)

Country Link
US (1) US12590086B2 (https=)
EP (1) EP4153581A1 (https=)
JP (3) JP2021183587A (https=)
KR (1) KR20230015946A (https=)
CN (1) CN116171276A (https=)
AR (1) AR122143A1 (https=)
AU (1) AU2021276623A1 (https=)
BR (1) BR112022023503A2 (https=)
CA (1) CA3178798A1 (https=)
IL (1) IL298275A (https=)
MX (1) MX2022014576A (https=)
TW (1) TW202208346A (https=)
WO (1) WO2021234451A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023528281A (ja) * 2020-05-22 2023-07-04 武田薬品工業株式会社 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202206054D0 (en) * 2022-04-26 2022-06-08 Cerevance Ltd Novel Compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500852A (ja) 1996-08-27 2001-01-23 プレーシス ファーマスーティカルズ インコーポレイテッド Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター
DE19736352C1 (de) 1997-08-21 1998-12-10 Atotech Deutschland Gmbh Vorrichtung zur Kontaktierung von flachem Behandlungsgut in Durchlaufgalvanisieranlagen
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
ATE448784T1 (de) 2002-02-14 2009-12-15 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
US8148367B2 (en) 2007-01-12 2012-04-03 Takeda Pharmaceutical Company Limited Renin inhibitors
WO2008094556A2 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
WO2011145735A1 (ja) 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2017222952A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
PL3829581T3 (pl) 2018-07-27 2024-07-01 Arcus Biosciences, Inc. Antagoniści pirydonu a2r
WO2020097609A1 (en) * 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
JP2020090111A (ja) 2018-12-03 2020-06-11 パイオニア株式会社 発光システム
JP2021183586A (ja) 2020-05-22 2021-12-02 武田薬品工業株式会社 複素環化合物
JP2021183587A (ja) 2020-05-22 2021-12-02 武田薬品工業株式会社 複素環化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023528281A (ja) * 2020-05-22 2023-07-04 武田薬品工業株式会社 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物
JP7734153B2 (ja) 2020-05-22 2025-09-04 武田薬品工業株式会社 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物

Also Published As

Publication number Publication date
KR20230015946A (ko) 2023-01-31
US12590086B2 (en) 2026-03-31
US20230357220A1 (en) 2023-11-09
TW202208346A (zh) 2022-03-01
AU2021276623A1 (en) 2022-12-22
AR122143A1 (es) 2022-08-17
CN116171276A (zh) 2023-05-26
WO2021234451A1 (en) 2021-11-25
JP7734153B2 (ja) 2025-09-04
IL298275A (en) 2023-01-01
MX2022014576A (es) 2023-02-14
EP4153581A1 (en) 2023-03-29
JP2023528281A (ja) 2023-07-04
CA3178798A1 (en) 2021-11-25
BR112022023503A2 (pt) 2023-01-17
JP2025170366A (ja) 2025-11-18

Similar Documents

Publication Publication Date Title
JP7379374B2 (ja) 複素環化合物
JP6957598B2 (ja) 置換ピロリジン化合物およびその用途
JP7012703B2 (ja) 置換ピロリジン化合物およびその用途
JP7665527B2 (ja) 複素環化合物
JPWO2020004536A1 (ja) 複素環化合物およびその用途
JP2022519331A (ja) 複素環化合物およびその用途
JPWO2020004537A1 (ja) 複素環化合物およびその用途
US11827601B2 (en) Heterocyclic NMDA antagonists
JP7592226B1 (ja) 複素環化合物
JP6675324B2 (ja) 複素環化合物
JP2025170366A (ja) 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物
JP2025168429A (ja) 例えば、うつ病を治療するための、ｇｐｒ１３９拮抗薬としての１－（（１ｈ－ピラゾール－４－イル）メチル）－３－（フェニル）－１，３－ジヒドロ－２ｈ－イミダゾール－２－オン誘導体および関連化合物
JPWO2020153414A1 (ja) 複素環化合物及びその用途
WO2020196828A1 (ja) 含窒素複素環化合物
AU2024237113A1 (en) Macrocyclic heterocycle compounds and use thereof
EA051899B1 (ru) Производные 3-((1н-пиразол-4-ил)метил)-6'-(фенил)-2н-(1,2'-бипиридин)-2-она и связанные с ними соединения как антагонисты рецептора gpr139 для применения в способе лечения, например, депрессии
JP2021050161A (ja) 複素環化合物及びその用途
JPWO2020067456A1 (ja) 複素環化合物